KR20220121850A - 항-cd73 항체 및 이의 용도 - Google Patents

항-cd73 항체 및 이의 용도 Download PDF

Info

Publication number
KR20220121850A
KR20220121850A KR1020227025615A KR20227025615A KR20220121850A KR 20220121850 A KR20220121850 A KR 20220121850A KR 1020227025615 A KR1020227025615 A KR 1020227025615A KR 20227025615 A KR20227025615 A KR 20227025615A KR 20220121850 A KR20220121850 A KR 20220121850A
Authority
KR
South Korea
Prior art keywords
seq
antibody
amino acid
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227025615A
Other languages
English (en)
Korean (ko)
Inventor
호라시오 지. 나스트리
숀 엠. 스튜어트
후안 카를로스 알마그로
징 저우
레베카 에이. 부온판
Original Assignee
인사이트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인사이트 코포레이션 filed Critical 인사이트 코포레이션
Publication of KR20220121850A publication Critical patent/KR20220121850A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227025615A 2020-01-03 2020-12-30 항-cd73 항체 및 이의 용도 Withdrawn KR20220121850A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062956847P 2020-01-03 2020-01-03
US62/956,847 2020-01-03
PCT/US2020/067533 WO2021138467A1 (en) 2020-01-03 2020-12-30 Anti-cd73 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20220121850A true KR20220121850A (ko) 2022-09-01

Family

ID=74347717

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227025615A Withdrawn KR20220121850A (ko) 2020-01-03 2020-12-30 항-cd73 항체 및 이의 용도

Country Status (19)

Country Link
US (2) US12018089B2 (enExample)
EP (1) EP4084825A1 (enExample)
JP (1) JP2023509448A (enExample)
KR (1) KR20220121850A (enExample)
CN (1) CN115135341A (enExample)
AR (1) AR120936A1 (enExample)
AU (1) AU2020417804A1 (enExample)
BR (1) BR112022013236A2 (enExample)
CA (1) CA3166533A1 (enExample)
CL (2) CL2022001769A1 (enExample)
CO (1) CO2022009248A2 (enExample)
CR (1) CR20220317A (enExample)
EC (1) ECSP22051701A (enExample)
IL (1) IL294436A (enExample)
MX (1) MX2022007575A (enExample)
PE (1) PE20221409A1 (enExample)
PH (1) PH12022551636A1 (enExample)
TW (1) TWI873265B (enExample)
WO (1) WO2021138467A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025135233A1 (ko) * 2023-12-21 2025-06-26 ㈜지아이이노베이션 Cd73에 특이적으로 결합하는 항체 및 이의 용도

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
PE20221409A1 (es) 2020-01-03 2022-09-20 Incyte Corp Anticuerpos anti-cd73 y usos de estos
TW202135823A (zh) 2020-01-03 2021-10-01 美商英塞特公司 Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法
TW202241441A (zh) * 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
CN113025567A (zh) * 2021-03-31 2021-06-25 中国人民解放军陆军特色医学中心 一种椎间盘单细胞的分离方法
EP4413366A4 (en) * 2021-10-08 2025-09-10 Tiberias Tech Hk Limited TIBTECH METHODS AND COMPOSITIONS FOR THE DETECTION OF CDH17
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025025190A1 (zh) * 2023-08-03 2025-02-06 贝达药业股份有限公司 抗cd73抗体及其应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
AU2001259142C1 (en) 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
EP1639014B1 (en) 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2006125140A2 (en) 2005-05-18 2006-11-23 Biogen Idec Inc. Methods for treating fibrotic conditions
JP5382692B2 (ja) 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
CA2848985A1 (en) * 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
EP3204417B1 (en) 2014-10-10 2020-07-22 Innate Pharma Cd73 blockade
WO2016131950A1 (en) 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
GB2537445A (en) 2014-11-10 2016-10-19 Medimmune Ltd Binding molecules specific for CD73 and uses thereof
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
CN114805575B (zh) 2015-12-09 2024-07-23 科尔沃斯制药股份有限公司 人源化抗cd73抗体
EP3423494A1 (en) * 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
RU2754058C2 (ru) 2016-12-13 2021-08-26 Астеллас Фарма Инк. Антитело к cd73 человека
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
US20210107989A1 (en) 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
US11530273B2 (en) 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
WO2019170131A1 (zh) 2018-03-07 2019-09-12 复旦大学 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
EP3762030A4 (en) * 2018-03-09 2022-01-05 Phanes Therapeutics, Inc. ANTI-CD73 ANTIBODIES AND USES THEREOF
WO2019173692A2 (en) * 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
BR112020020826A2 (pt) 2018-04-12 2021-01-19 Bristol-Myers Squibb Company Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
WO2019232244A2 (en) * 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
MX2021005248A (es) 2018-11-05 2021-08-11 Corvus Pharmaceuticals Inc Anticuerpos contra cd73 activadores de células b.
US20220220218A1 (en) 2018-11-12 2022-07-14 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
CN111499747B (zh) 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
CN111434688A (zh) 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
MX2021012769A (es) 2019-04-23 2021-11-18 Innate Pharma Anticuerpos bloqueadores cd73.
JP7623706B2 (ja) 2019-06-06 2025-01-29 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド Ｃｄ７３に特異的な結合分子と結合分子の使用
CN117946274B (zh) 2019-06-19 2026-02-17 杭州博之锐生物制药有限公司 抗cd73抗体及其应用
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
JP7471016B2 (ja) 2019-08-21 2024-04-19 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド 抗ｃｄ７３抗体およびその適用
PE20230372A1 (es) 2019-08-26 2023-03-06 Incyte Corp Triazolopirimidinas como inhibidores de a2a/a2b
UA130408C2 (uk) 2019-09-06 2026-02-11 Ле Лаборатуар Сервьє Антитіла до cd73
US20240218073A1 (en) 2019-11-01 2024-07-04 Corvus Pharmaceuticals, Inc. Immunomodulatory anti-cd73 antibodies and uses thereof
CA3161717A1 (en) 2019-11-15 2021-05-20 Dana LORD Biparatopic cd73 antibodies
CA3165384A1 (en) 2019-12-19 2021-06-24 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
TW202135823A (zh) 2020-01-03 2021-10-01 美商英塞特公司 Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法
PE20221409A1 (es) 2020-01-03 2022-09-20 Incyte Corp Anticuerpos anti-cd73 y usos de estos
CA3174033A1 (en) 2020-04-09 2021-10-14 Sang Hoon Cha Monoclonal antibodies and antigen binding fragments thereof for suppressing cd73 immune checkpoint and uses thereof
US20230159655A1 (en) 2020-04-22 2023-05-25 Akeso Biopharma, Inc Anti-cd73 antibody and use thereof
CN115551888B (zh) 2020-05-12 2026-04-28 百欧恩泰(珠海)医药研发有限公司 抗cd73抗体及其用途
EP4159763A4 (en) 2020-05-29 2024-06-12 BrightPath Biotherapeutics Co., Ltd. ANTI-CD73 ANTIBODIES AND USE THEREOF
JP2023532234A (ja) 2020-06-22 2023-07-27 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ｃｄ７３抗体とその用途
TW202241441A (zh) 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025135233A1 (ko) * 2023-12-21 2025-06-26 ㈜지아이이노베이션 Cd73에 특이적으로 결합하는 항체 및 이의 용도

Also Published As

Publication number Publication date
CL2024002235A1 (es) 2024-12-27
BR112022013236A2 (pt) 2022-09-06
CR20220317A (es) 2022-09-02
JP2023509448A (ja) 2023-03-08
ECSP22051701A (es) 2022-08-31
PE20221409A1 (es) 2022-09-20
CL2022001769A1 (es) 2023-01-20
US12018089B2 (en) 2024-06-25
AU2020417804A1 (en) 2022-07-21
US20210230293A1 (en) 2021-07-29
IL294436A (en) 2022-09-01
AR120936A1 (es) 2022-03-30
CO2022009248A2 (es) 2022-08-19
TWI873265B (zh) 2025-02-21
PH12022551636A1 (en) 2024-01-08
CN115135341A (zh) 2022-09-30
MX2022007575A (es) 2022-09-23
EP4084825A1 (en) 2022-11-09
WO2021138467A1 (en) 2021-07-08
US20240352143A1 (en) 2024-10-24
TW202128768A (zh) 2021-08-01
CA3166533A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
TWI873265B (zh) 抗ｃｄ７３抗體及其用途
RU2725811C1 (ru) Антитела против 4-1bb человека и их применение
KR102584675B1 (ko) GUCY2c에 특이적인 항체 및 이의 용도
JP6163158B2 (ja) Ｃｄ４０ｌに拮抗する抗体ポリペプチド
JP6839772B2 (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
JP6212493B2 (ja) 抗ｃｄ１３４（ｏｘ４０）抗体およびその使用
JP2024059872A (ja) 新規抗ｃｃｒ８抗体
JP2020504095A (ja) 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体
KR20240046533A (ko) 항-ccr8 항체 및 그것의 용도
CN107835820A (zh) 识别癌症特异性IL13Rα2的CAR T细胞
JP2022507253A (ja) チェックポイント分子に対する多重特異性結合性構築物およびその使用
KR20220088847A (ko) 항-vsig4 항체 또는 항원-결합 단편 및 이들의 용도
KR20230166120A (ko) 새로운 tnfr2 결합 분자
TW202302645A (zh) 抗vsig4抗體或抗原結合片段及其用途
US10626183B2 (en) IFN-γ-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof
EA049477B1 (ru) Антитела против cd73 и их применение
JP7692185B2 (ja) 抗ｃｄ４０抗体及びその用途
RU2777573C2 (ru) Антитела против 4-1bb человека и их применение
HK40007669A (en) IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF
HK40006081B (en) Anti-human 4-1 bb antibodies and use thereof
HK40006081A (en) Anti-human 4-1 bb antibodies and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202